sur Pentixapharm Holding AG (isin : DE000A40AEG0)
Pentixapharm Holding AG Announces Leadership Changes
Berlin, Germany, October 25, 2024 - Pentixapharm Holding AG has announced significant changes in its management and supervisory boards, effective at the end of October 2024. Dr. Hakim Bouterfa, the founder and CEO, will step down from his management roles to join the Supervisory Board, following a nomination by major shareholder Eckert Wagniskapital und Frühphasenfinanzierung GmbH.
Nuclear medicine expert Prof. Dr. Ken Herrmann will join the Supervisory Board, replacing physicist Paola Eckert-Palvarini. Meanwhile, Dr. Andreas Eckert will temporarily serve as Executive Chairman, with Frank Perschmann as Chairman of the Supervisory Board.
Dr. Dirk Pleimes has been appointed as CEO of Pentixapharm AG, continuing his role as Chief Medical Officer. These adjustments mark the end of the company's spin-off from Eckert & Ziegler SE, with full details available soon on the company's website.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Pentixapharm Holding AG